Mirdametinib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications

Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth.

Mirdametinib and abemaciclib cooperate in atypical teratoid rhabdoid tumor to decrease proliferation and suppress tumor growth.

Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas.

Journal: Expert review of anticancer therapy
Published: March 12, 2026

MEK inhibitor Mirdametinib promotes fracture healing in osteofibrous dysplasia RASopathy.

MEK inhibitor Mirdametinib promotes fracture healing in osteofibrous dysplasia RASopathy.

Journal: The Journal of clinical investigation
Published: February 26, 2026

Mechanical Stiffening Promotes Growth, Invasion, and Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitor Resistance in 3D Plexiform Neurofibroma Cultures.

Mechanical Stiffening Promotes Growth, Invasion, and Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitor Resistance in 3D Plexiform Neurofibroma Cultures.

Journal: bioRxiv : the preprint server for biology
Published: February 09, 2026

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.

Journal: Pharmacological research
Published: January 20, 2026

Prolonged Mitogen-Activated Protein Kinase Kinase (MEK) Inhibition Induces Increase in Proteolysis and Compensatory Phosphorylation of MEK and Protein Kinase B (AKT) in Plexiform Neurofibroma Cells.

Prolonged Mitogen-Activated Protein Kinase Kinase (MEK) Inhibition Induces Increase in Proteolysis and Compensatory Phosphorylation of MEK and Protein Kinase B (AKT) in Plexiform Neurofibroma Cells.

Journal: Cells
Published: January 05, 2026

Trametinib and Fimepinostat Induce Malignant Peripheral Nerve Sheath Tumor Cell Death In Vitro.

Trametinib and Fimepinostat Induce Malignant Peripheral Nerve Sheath Tumor Cell Death In Vitro.

Journal: Cancers
Published: December 05, 2025

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma.

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastoma.

Journal: bioRxiv : the preprint server for biology
Published: December 03, 2025

Liposomes and macrophage membrane co-assembled biomimetic nanoparticles alleviate cardiac insufficiency after myocardial infarction.

Liposomes and macrophage membrane co-assembled biomimetic nanoparticles alleviate cardiac insufficiency after myocardial infarction.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 22, 2025

FDA approval of mirdametinib for NF1-associated plexiform neurofibromas: clinical and regulatory perspectives.

FDA approval of mirdametinib for NF1-associated plexiform neurofibromas: clinical and regulatory perspectives.

Journal: Annals of medicine and surgery (2012)
Published: October 13, 2025

Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives.

Recent FDA-approved kinase inhibitors for cancer therapy in 2025: A comprehensive review and perspectives.

Journal: EXCLI journal
Published: September 28, 2025

Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas.

Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas.

Journal: Expert opinion on investigational drugs
Published: September 11, 2025
Showing 1-12 of 53

Last Updated: 04/28/2026